To further characterize the selectivity, mechanism of action, and therapeutic efficacy of the novel small molecule inhibitor, SKI-178.
INTRODUCTION
Numerous studies have demonstrated that the sphingosine kinases (SphK1 and/or 2) are overexpressed in cancer. [1] [2] [3] [4] [5] [6] [7] Elevated expression of SphK1 is recognized as a risk factor for decreased 5-year survival and decreased progression-free survival in numerous solid and hematological cancers (summarized in a recent meta-analysis). 8 Overexpression of SphK1 and more recently SphK2 has been associated with oncogenic transformation and growth in soft agar. [9] [10] [11] In a cancerous setting, overexpression of the SphKs deregulates the "sphingolipid rheostat, " increasing sphingosine-1-phosphate (S1P) production at the expense of ceramide (Cer)/sphingosine. Thus, S1P-driven pro-mitogenic/pro-survival signaling predominates and cancer cells become dependent upon S1P signaling ("nononcogene" addiction). 12 Sph/Cer are thought to be important for induction of apoptosis, and SphK overexpression also effectively depletes Sph/Cer levels in cancer cells, making them more resistant to chemotherapies. Hence, it was proposed that inhibition of SphK accomplished two effects simultaneously, decreasing pro-mitogenic/pro-survival S1P signaling and increasing levels of pro-apoptotic sphingolipids (Sph/Cer), providing a strong rationale for the development of sphingosine kinase inhibitors (SKIs) as anticancer therapeutic agents.
In 2002, we were the first group to identify four classes of potent, nonlipid-based, "drug-like" small molecule inhibitors of SphK (SKI-I-IV). 1 One of these compounds, SKI-II, has been used extensively in the literature and was recently co-crystalized with SphK1. 13 Like SKI-II, other "first-generation" SKIs, such as N, N-dimethyl sphingosine, SK1-I, and ABC294640, induced apoptosis, reduced tumor volume in numerous animal studies, and provided encouraging results that SKIs would be effective therapeutic agents for multiple cancer types. 1, [14] [15] [16] [17] Based on these early successes, several groups have separately developed "second-generation, " isoform-selective, nanomolar potency SphK inhibitors (based on in vitro studies) that, unlike the "first-generation" SKIs, were unable to induce apoptosis of an array of cancer cell lines, although they too inhibited S1P production and induced intracellular Cer accumulation. [18] [19] [20] [21] [22] [23] The discouraging results with these "second-generation" inhibitors have called into question whether the SphKs are therapeutic targets for cancer. 19 Concurrent with the development of these "second-generation" inhibitors, we initiated studies to optimize our SKI-I chemotype for further development as an anticancer therapeutic strategy due to the fact that SKI-I was the most potently cytotoxic of the four originally identified chemotypes. Through a series of structure-activity relationship studies, we identified a refined SKI-I analog (SKI-178) that competes for the Sph-binding site in SphK1. SKI-178 effectively reduces S1P formation while inducing Cer accumulation and in contrast to other "second-generation" SKIs, it is potently cytotoxic against a broad range of cancer cell lines. 24 Further investigation of the apoptotic mechanism of action of SKI-178 demonstrated that apoptotic cell death is the direct result of prolonged cyclin-dependent kinase 1 (CDK1) activation during mitotic arrest. 25 This prolonged activation of CDK1 leads to the sustained phosphorylation and inhibition of various anti-apoptotic Bcl-2 family members including Bcl-2, Bcl-xl, and Mcl-1. 25 While there is some evidence in the literature to suggest a link between SphK1 inhibition and mitotic arrest, 26, 27 the apparent discrepancy between the actions of SKI-178 and the other noncytotoxic SphK1 inhibitors has led us to suspect that SKI-178 has multiple cellular targets that account for the ability of SKI-178 to induce apoptosis. 26, 27 Thus, the goal of these studies is to clarify the target selectivity of SKI-178 and to evaluate the therapeutic potential of SKI-178 as a multitargeted agent for the treatment of solid and hematological cancers.
METHODS

Animal studies
All animal studies reported in this manuscript were conducted ethically under the guidance and approval of the Penn State University Park and Penn State Hershey IACUC committees.
Reagents
SKI-178
(N'-[(1E)-1-(3,4-dimethoxyphenyl) ethylidene]-3-(4-methoxxyphenyl)-1H-pyrazole-5-carbohydrazide) was synthesized as described previously. 24 Reagents were purchased as follows: vincristine (Thermo Fisher Scientific, Waltham, MA, USA), Colchicine (Enzo Life Sciences, Farmingdale, NY, USA), Paclitaxel (Sigma-Aldrich, St. Louis, MO, USA), MG132 (Sigma-Aldrich, St. Louis, MO, USA) and PF-543 (Selleck Chemicals, Houston, TX, USA), antibodies against SphK1, pBcl-2 (Ser70), Cleaved caspase-7, and Tubulin (Cell Signaling Technology, Danvers, MA, USA), SphK1 (pSer225) (ECM Biosciences, Versailles, KY, USA), and GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA, USA). β-hydroxypropyl-cyclodextrin (β-HPCD) was from Acros (NJ, USA). 1,2-propanediol, Tween-20, and dextrose were from Sigma-Aldrich (MO, USA). 
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HEK293 cells, overexpressing His 6X -SphK2, were generated and cultured as described. 28 All cell lines were maintained at 37°C with 5% CO 2 in a humidified incubator.
Whole-cell analysis of tubulin polymerization
Microtubules were fixed and stained as previously described. 29 Cells were treated in 24-well plates with vincristine, paclitaxel, SKI-178, or PF-543 for 18 h. Cells were pelleted by centrifugation at 600 ×g for 5 min. Cell pellets were resuspended and fixed with 1 mL of 0.5% glutaraldehyde in microtubule-stabilizing buffer (80 mM PIPES [pH 6.8] 1 mM MgCl 2 , 5 mM EDTA, and 0.5% Triton X-100) for 10 min at room temperature. Glutaraldehyde was quenched with 0.7 mL of 1 mg/mL NaBH 4 in 1× phosphate-buffered saline (PBS) and cells were subsequently pelleted at 1000 ×g for 7 min. Cell pellet was resuspended in 20 µL of 50 µg/mL RNase A in antibody dilution solution (1× PBS [pH 7.4], 0.2% Triton X-100, 2% bovine serum albumin, 0.1% NaN 3 ) and incubated at 4°C overnight. The next morning, 5 µL of a 1:50 dilution of anti-α-tubulin-FITC antibody in antibody dilution solution was added to the 20 µL suspension to achieve a final antibody dilution of 1:250 and incubated for 3 h protected from light. Samples were further diluted in 200 µL of 50 µg/mL propidium iodide in 1× PBS. Cells were analyzed by flow cytometry on a BD FACSCalibur (BD Biosciences, San Jose, CA, USA) and results were analyzed by ModFit LT (Verity Software House, Topsham, ME, USA).
In vitro tubulin polymerization assay
Inhibition of tubulin polymerization was measured using the Cytoskeleton HTS-Tubulin Polymerization Assay Kit (Cytoskeleton, Inc., Denver, CO, USA) as per manufacturer's instructions. The assay contained 100 µL of 4 mg/mL tubulin in G-PEM buffer (80 mM PIPES, pH 6.9, 0.5 mM EGTA, 2 mM MgCl 2 , and 1 mM GTP). Totally, 10 µL of × 10 PF-543, vincristine, and SKI-178 were prewarmed to 37°C in a half area 96-well plate (10 µL dimethyl sulfoxide was used as control). The polymerization of purified tubulin into microtubules was carried out at 37°C, and light scattering was recorded at 340 nm every minute for 60 min. 
Western blot analysis
Briefly, whole-cell lysates were harvested in 100 µL 1× RIPA buffer (20 mM tris-HCL [pH 7.5], 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxycholate, 5 mM sodium pyrophosphate, 1 mM β-glycerol phosphate, 1 mM sodium orthovanadate, 30 mM sodium fluoride, and complete protease inhibitor cocktail tablet [Roche Diagnostics, Mannheim, Germany]). Lysates were centrifuged (20,000 ×g) for 15 min at 4°C to remove cell debris. Total protein concentrations were quantified using the BCA assay from Pierce (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of denatured total protein were resolved by NuPAGE 4%-12% Bis-Tris gel electrophoresis (Life Technologies Carlsbad, CA, USA) and transferred to PVDF membranes (Life Technologies Carlsbad, CA, USA). Membranes were blocked for 1 h at room temperature in 5% milk/tris-buffered saline-Tween, incubated overnight at 4°C with primary antibodies (1:1000), and immunodetection was done with corresponding secondary IgG HRP-linked antibodies (1:5000) using the ECL chemiluminescence reagents (Thermo Fisher Scientific, Waltham, MA, USA).
Analysis of apoptosis
HL-60 cells were treated with PF-543, vincristine, colchicine, or combinations thereof, for 48 h. Stages of apoptosis were assayed using the MUSE™ Annexin V and Dead Cell kit combined with laser-based fluorescence detection using a MUSE™ cell analyzer (EMD Millipore, Billerica, MA, USA) according to the manufacturers' recommendations.
Cellular thermal shift assay
Direct target engagement of SphK1, SphK2, and β-Tubulin was performed as described in with some minor modification. 30 Briefly, nearly confluent 10 cm culture dishes of HEK293 cells, overexpressing either His 6X -SphK1 or His 6X -SphK2, were treated with either vehicle control or SKI-178 for 16 h. Cells were collected by trypsinization, neutralized by the addition of DMEM containing 10% FBS, pelleted at 300 ×g for 5 min, and washed with 1× PBS. After washing, cells were pelleted again at 300 ×g for 5 min and resuspended in 1 mL of 20 mM Tris pH 7.4 containing a complete protease inhibitor cocktail tablet (Roche Diagnostics, Mannheim, Germany). Totally, 100 µL aliquots of the cell suspension were heated to designated temperatures for 3 min. After cooling for 3 min at room temperature, cells were freeze-thawed three times with liquid nitrogen, and the soluble fraction (lysate) was separated from cell debris as well as the precipitated and aggregated proteins by centrifugation at 20,000 ×g for 20 min at 4°C. The supernatant was transferred to a new tube and quantification of the remaining soluble protein was achieved by Western blot analysis.
MLL-AF9 retroviral transduction model of acute myeloid leukemia
Viral stocks were generated in HEK293T cells as described previously. 31 In the MLL-AF9 model, bone marrow (BM) cells from B6.SJLPtprc ) were transplanted by retro-orbital injection into C57BL/6 (CD45.2+) recipient mice that were preconditioned with 950 rads of irradiation. Six to eight weeks after transplantation, engraftment was confirmed by measurement of white blood cell (WBC) counts in peripheral blood (WBCs ≥ 10 4 /µL were indicative of AML). SKI-178 dissolved in 45% β-HPCD or vehicle control was administered by retro-orbital injection under isoflurane anesthesia every other day for the time periods as indicated below. For secondary transplantation experiments, mice treated with SKI-178 for 10 weeks were euthanized; spleen cells were isolated and transplanted into irradiated secondary C57BL/6 (CD45.2+) recipients. Six weeks after secondary transplantation, mice were analyzed for WBC counts. 33 SKI-178 dissolved in 30% v/v 1,2-propanediol, 5% v/v Tween-20, and 65% v/v of 5% dextrose in double-distilled water or vehicle control was administered to mice at 5 mg/kg body weight beginning day 4 by retro-orbital injection every other day under isoflurane anesthesia.
RESULTS
SKI-178 directly target engages sphingosine kinase 1 and 2 protein in cells
Our initial characterization of the SphK inhibitory activity of SKI-178 relied on in vitro SphK activity assays using recombinant SphK1 and SphK2 proteins and isoform-selective biochemical buffers using standard published assay conditions. 34 In addition, we employed liquid chromatography-mass spectrometry/mass spectrometry techniques to measure the depletion of S1P/accumulation of Cer species. However, these techniques are fundamentally lacking in that they do not demonstrate that SKI-178 was able to bind to and directly "target engage" either SphK protein in intact cells. Demonstration of "direct target engagement" has taken on a heightened importance in recent years due to the Phase III Clinical Trial failure of Iniparib. 35 To confirm that SKI-178 directly binds SphK1 and SphK2, we employed the recently developed cellular thermal shift assay (CETSA) to monitor direct binding of SKI-178 to SphK1 and SphK2 in the context of intact cells. 30, 36 With this assay, the binding of a ligand, such as SKI-178, to target proteins alters their thermal stability which can be monitored by comparing the amount of protein remaining in solution after temperature-induced protein aggregates have been removed by centrifugation. The outputs from this assay allow for the comparison between temperature-induced protein aggregation curves and are used to evaluate drug target engagement in cells.
To easily and reliably demonstrate "direct target engagement" of SphK1 and SphK2, we employed HEK293 cells that stably The corresponding stable overexpression cell lines were treated with SKI-178 for 16 h, after which multiple aliquots of the cell suspension were heated over a temperature gradient that was empirically determined for both SphK1 and SphK2. Cells were subsequently lysed and centrifuged to separate soluble fractions from precipitated denatured proteins. The binding of SKI-178 to SphK1 and/or SphK2 should alter their melting curves by either stabilizing or destabilizing the proteins. The presence of SphK1 and SphK2 in the soluble fraction after thermal denaturation was examined by Western blotting. As shown in Figure 1a , relative to control, cells treated with SKI-178 show a marked increase in the accumulation of SphK1 protein in the soluble fraction at all temperatures examined, indicating the binding of SKI-178 stabilized SphK1 protein. Since SphK1 is known to be activated by phosphorylation at Ser225 by ERK1/2 activity, we confirmed that SKI-178 is also able to bind to active pSphK1 (Ser225) at all temperatures examined. 37 These data provide direct evidence that Figure 1b ] indicating that SKI-178 is capable of direct target engagement of SphK2. Therefore, these data indicate that SKI-178 is not SphK1 selective, as we had previously reported, but is instead a nonisoform-selective SphK1/2 inhibitor. Knowing the temperature at which SphK1 denatures and precipitates allows us to employ a variation of these studies termed isothermal dose-response fingerprint (ITDRF CETSA ). 36 With this experimental design, the stabilization or destabilization of a protein can be monitored as a function of increasing drug concentration. 30 This allows for determination of the IC 50 of SKI-178 stabilization of both SphK1 and SphK2 in cells. To this end, His 6X -SphK1 and His 6X -SphK2 cells were again treated for 16 h with a 1:2 serial dilution of SKI-178 and subsequently heated to 60°C and 63°C, respectively. As shown in Figure 1c , SKI-178 dose dependently binds and significantly stabilizes both SphK1 and SphK2 proteins. The concentrations of SKI-178 required to bind both SphK1 and SphK2 correlate well with the published cytotoxic IC 50 of SKI-178 which ranges from about 400 to 800 nM depending on the cell line. 25 Therefore, SKI-178 directly binds and inhibits SphK1 and SphK2 at concentrations required to induce apoptotic cell death. Together, these results further establish SKI-178 as a relevant inhibitor of SphK kinase activity in intact cells.
SKI-178 directly impairs microtubule assembly
The data presented above corroborate the SphK inhibitory potential of SKI-178, however, given the recent studies that suggest that SphK inhibition does not induce apoptosis; it would be imprudent to ignore the possibility of off-target effects leading to SKI-178-induced apoptosis. As stated above, we have previously determined that SKI-178-induced apoptosis depends on sustained CDK1 activation and sustained mitotic arrest. Examination of the literature revealed that, similar to SKI-178, a group of anticancer drugs, termed microtubule-targeting agents (MTA), disrupt the dynamic equilibrium of the mitotic spindles, leading to prolonged mitotic arrest and apoptotic cell death as a result of sustained activation of CDK1. 38 Based on the striking similarity between the MOA of SKI-178 and various agents that target microtubules, we investigated the possibility that SKI-178, in addition to being a SphK inhibitor, also works as an MTA.
To visually examine the effects of SKI-178 on microtubule dynamics, U-251-MG glioblastoma cells, overexpressing GFP-tagged α-tubulin, were treated with either SKI-178 or PF-543, a noncytotoxic but highly potent inhibitor of SphK1. As shown in Figure 2a , SKI-178, but not PF-543, significantly disrupts the microtubule network relative to a vehicle-treated control. To further assess the effects of SKI-178 on microtubule polymerization, a previously described whole-cell microtubule assay was performed to quantify the effects of SKI-178 on tubulin polymerization, in intact cells, using flow cytometry. 29 As would be expected, relative to a vehicle control, the MTA vincristine decreased tubulin fluorescence, while the microtubule-stabilizing agent, paclitaxel, increased fluorescence. SKI-178 destabilizes microtubule polymerization similar to that of vincristine [ Figure 2b ], whereas PF-543 had no effect on microtubule polymerization. The fact that PF-543 has no effect on microtubule polymerization indicates that SphK inhibition, by SKI-178, does not contribute to its effects on microtubule disruption.
To determine whether this was a direct or indirect effect on tubulin polymerization, an in vitro tubulin polymerization assay was employed. As shown in Figure 2c , SKI-178 dose dependently decreased the rate of tubulin polymerization relative to vehicle-treated control, while PF-543 had little to no effect. These results confirm that, in a cell-free system, SKI-178 can directly bind to and inhibit tubulin polymerization similar to that of vincristine. These results, in combination with the SphK CETSA data as shown in Figure 1 , provide direct evidence that SKI-178 can target engage both SphK and tubulin proteins in cells, suggesting that SKI-178 might be a multitargeted inhibitor capable of binding to and disrupting the functions of two relevant chemotherapeutic targets.
Sphingosine kinase 1 inhibition sensitizes cells to the effects of microtubule disruption
The data described above suggest that SKI-178 functions as a multitargeted inhibitor of both SphKs and microtubule dynamics. Interestingly, numerous studies have linked sphingolipid metabolites to the actions of MTAs such as paclitaxel, colchicine, and the vinca alkaloids. Indeed, SKIs, other inhibitors of Cer metabolism, and Cer itself all synergistically enhance the apoptotic efficacy of MTAs. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] More recently, it has been suggested that Cer may actually be required for paclitaxel-induced mitochondrial outer membrane permeabilization (MOMP) and apoptosis. 50 Mechanistically, sphingolipids have also been shown to activate the pro-apoptotic Bcl-2 family proteins Bak and Bax. 51 Other studies have shown that upon activation, Bax and Bak bind to mitochondrial Cer and organize the formation of Cer-containing channels leading to MOMP and apoptosis. [52] [53] [54] [55] [56] Given the established synergism between sphingolipid metabolites and MTAs, we reasoned that combined inhibition of the two major targets of SKI-178 (namely, SphK and microtubules) either as a single agent (SKI-178) or using multiple agents (i.e., SKI and MTA, in combination) can synergistically act to induce apoptosis of cancer cells such as AML cell lines. 57 Therefore, to demonstrate that SphK inhibition could sensitize cells to microtubule disruption independently of SKI-178, we used the MTA vincristine in combination with PF-543, the most potent and selective inhibitor of SphK1 currently available. We hypothesized that SKI-178 alone exerts the same effect as these agents in combination. To determine whether SphK1 inhibition by PF-543 could sensitize cells to vincristine, HL-60 cells were treated with noncytotoxic doses of either compound alone or in combination, and the percentage of total apoptosis was quantified by Annexin V-positive staining. Our results showed that while there was no induction of apoptotic cell death with either 6 nM vincristine or 5 µM PF-543, in combination, we observed a statistically significant increase in the percentage of total apoptotic cells [ Figure 3a and b]. As a control, we observed significant induction of apoptosis by 5 µM SKI-178 [ Figure 3c and d], consistent with our previous observations. 25 We previously demonstrated that CDK1-mediated phosphorylation at Ser70 and inhibition of anti-apoptotic Bcl-2 proteins underlies SKI-178-induced apoptotic cell death. Similar to SKI-178, vincristine is also known to induce the inhibitory phosphorylation of anti-apoptotic Bcl-2 proteins which has likewise been linked to prolonged CDK1 activity. [58] [59] [60] Therefore, it is possible that SphK1 inhibition with PF-543 could act cooperatively with vincristine to enhance these effects. As shown in Figure 3e , we showed that in HL-60 cells, treatment with a noncytotoxic dose of vincristine (3 nM) induces Bcl-2 phosphorylation. However, when combined with 6.25 µM PF-543, which on its own also has minimal effect, levels of Bcl-2 phosphorylation are dramatically enhanced. While caspase-7 cleavage was not examined, it is clear from the results presented in Figure 3a and b that the combination of vincristine and PF-543 significantly induces apoptotic cell death.
To confirm that these effects were not specific to vincristine, we employed combretastatin A4, another MTA that induces apoptotic cell death through disruption of microtubule polymerization-like vincristine. 61 We again treated HL-60 cells with noncytotoxic doses of either combretastatin A4 or PF-543 alone or in combination. The percentage of total apoptotic cells was quantified by Annexin V-positive staining. While 1.25 nM combretastatin A4 alone led to an approximately 2.5-fold increase in apoptotic cell death, the combination with a noncytotoxic dose of PF-543 (5 µM) almost doubled this effect [ Figure 3f and g]. These results support the hypothesis that SphK1 inhibition can sensitize cells to the effects of various MTAs. SKI-178 exerts both of these effects as a single agent and is therefore a novel and promising chemotherapeutic approach and suggests that further development of SKI-178 may still be warranted if efficacy could be demonstrated in a mouse model of cancer.
Determination of the toxicity profile of SKI-178 in naïve mice
We recognize that any investigational drug can potentially have dose-limiting toxicity; thus, to initially evaluate the toxicity profile of SKI-178, before disease efficacy determination, we determined the maximum tolerated dosage (MTD) of SKI-178 in naïve Swiss-Webster mice. SKI-178 was delivered through tail-vein injection dissolved in 45% w/v β-HPCD in 1 × PBS at a dose of 80 mg/kg (n = 3). At this dose, all animals displayed no signs of overt toxicity and survived 24 h. We escalated the dosage of SKI-178 to 100 mg/kg and observed transient lethargy (15 min) after which the animals recovered and survived 24 h. Further escalation of the dosage to 200 mg/kg resulted in severe lethargy and the animals were euthanized. Given the transient lethargy at 100 mg/kg, we established 80 mg/kg as an approximate MTD for SKI-178.
Repeated dosage at 80 mg/kg every day for 3 days was well tolerated with no body weight loss (data not shown). To further examine the potential toxicological and hematopoietic effects of SKI-178, we performed a repeated dose study of SKI-178 in naïve Swiss-Webster mice. SKI-178 (in 45% β-HPCD) was injected daily, through tail-vein, for 14 days at ½ and ¼ MTD (40 mg/kg and 20 mg/kg, respectively). As shown in Figure 4 , SKI-178 was well tolerated at both doses over the 14-day injection period, with no apparent body weight loss at either dose. Complete blood counts and serum clinical chemistry demonstrated that SKI-178 at 40 mg/kg appears to be well tolerated [ Supplementary Tables 1 and 2 ].
SKI-178 induces complete remission in the MLL-AF9 mouse model system
Investigators have actively pursued the development of mouse models that accurately reflect the clinical pathology of the cancers that they wish to study. Orthotopic implantation models are generally considered to be a more accurate reflection of the proper tumor microenvironment relative to subcutaneous xenograft models. Similarly, immune-competent models with intact immune systems and bearing syngeneic tumor models have a decided advantage over immuno-compromised mouse models. On the other hand, the immune-compromised models allow engraftment of human cancer cell lines. Clearly, no single mouse model can directly predict the therapeutic efficacy of a developmental compound such as SKI-178. Thus, performing proof-of-concept animal studies in multiple models of both hematological and solid tumor models may provide a more accurate estimation of the therapeutic potential of a multitargeted agent such as SKI-178.
To this end, one model system we have chosen to employ in our assessment of SKI-178 is an immunocompetent murine AML model induced by the MLL-AF9 (MLL/MLLT3) fusion oncogene that allows growth of cells with features consistent with a leukemic stem cell (LSC) phenotype. MLL-AF9 arises as a reciprocal translocation of the AF9 gene on chromosome 9p22 and the aforementioned MLL gene on chromosome 11q23. 62 In patients, MLL-AF9-expressing AML cells are consistent with myelomonocytic differentiation and are associated with an aggressive disease and poor prognosis. 62 Knock-in and retroviral gene transfer mouse models of MLL-AF9 closely parallel human patient AML making these models an appropriate system with which to examine new therapeutic strategies for treatment of AML. 62 As shown in Figure 5a , we generated MLL-AF9 transduced Kit + Sca1 + Lin − hematopoietic stem cells and transplanted them into irradiated recipients to generate AML mice. Donor and recipient cells were differentiated using CD45.1 and CD45.2 alleles as indicated and GFP was used to distinguish MLL-AF9-expressing cells. Mice confirmed to have WBC counts > 10 4 cells/µL after BM transplant were considered to have developed AML.
To determine the in vivo efficacy of SKI-178 in the MLL-AF9 mouse model system, leukemic mice were divided into vehicle and SKI-178 treatment groups (n = 5/group). SKI-178 (20 mg/kg) was administered to mice every other day in 45% β-HPCD vehicle. As shown in Figure 5b , PB samples were obtained from vehicle-treated and SKI-178-treated groups after 1 and 3 weeks of treatment administration. Among the vehicle-treated controls, WBC counts increased with time from their initial ~10 4 cells/µL levels to > 7 × 10 4 cells/µL after 3 weeks of treatment. In contrast, after 1 week of treatment with SKI-178, WBC counts decreased from their initial 10 4 cells/µL levels and continued to decline after 3 weeks of treatment until they reached normal levels (~4 × 10 3 cells/µL). Two vehicle-treated mice died within 1 week of initiation of treatment and after 4 weeks of treatment, and the remaining three vehicle-treated mice were found to be moribund and were sacrificed [ Figure 5c ]. In contrast, all 5 SKI-178-treated mice were healthy, active, and continued to receive SKI-178 treatment Qod for 19 weeks without weight loss or any overt signs of toxicity.
SKI-178 treatment results in a dose-dependent increase in survival
To confirm and extend these findings, we next determined whether SKI-178 acted in a dose-dependent manner by initiating treatments at three different dosages (20, 10, and 5 mg/kg). Again, MLL-AF9 + mice displaying signs of leukemia were divided into vehicle and treatment cohorts (n = 5/group) and retro-orbitally injected with SKI-178 at the different dosages Qod. After 1 week of treatment, WBC counts were determined for all treatment groups and compared to pretreatment WBC counts. As shown in Figure 6a , after 1 week of treatment, WBC counts increased significantly in vehicle-treated mice consistent with the previous study. Also consistent with the previous study, we observed a significant reduction in WBC counts in the 20 mg/kg SKI-178 treatment groups with WBC counts returning to the normal range. The SKI-178-mediated decrease in WBC counts was also observed in the 10 mg/kg treatment group. The 5 mg/kg SKI-178 treatment group displayed essentially no change in WBC counts after 1 week of treatment.
As shown in Figure 6b , after 2 weeks of treatment, all 5 vehicle-treated mice succumbed to AML. Similarly, all 5 of the 5 mg/kg SKI-178 treatment group died within 3 weeks of the initiation of treatment. In contrast, 4 of 5 of the 10 mg/kg SKI-178-treated group and all 5 of the 20 mg/kg SKI-178-treated group survived the entire course of the treatment period (10 weeks). After 10 weeks of treatment, the surviving 10 and 20 mg/kg SKI-178-treated mice were euthanized and peripheral blood WBC counts and the presence of MLL-AF9 + cells in the BM and spleen were analyzed by flow cytometry. Representative samples of BM and spleen from both 10 and 20 mg/kg SKI-178-treated mice demonstrated that CD45.2 + cells were not detected in either the BM or spleen samples from the 20 mg/kg SKI-178-treated mice. Similarly, few to no CD45.2 + WBCs were detected in the 10 mg/kg SKI-178-treated BM and spleen samples [ Figure 6c ]. The WBC counts returned to normal values (data not shown). Eighty percent of the mice treated with 10 mg/kg SKI-178 survived and at 10 weeks posttreatment appeared to be leukemia free. However, the kinetics of recovery were different in this group compared to the 20 mg/kg treatment group. At 5 weeks of treatment, the 10 mg/kg treatment group still exhibited MLL-AF9 + cells in the peripheral blood while the 20 mg/kg treatment group had no detectable MLL-AF9 cells (data not shown). Taken together with the survival data, the absence of MLL-AF9 + AML cells from both BM and spleen of both the 10 mg/kg and 20 mg/kg SKI-178-treated mice strongly suggest that SKI-178 is capable of inducing complete remission of MLL-AF9 leukemia in this mouse model.
A major impediment to long-term treatment for AML is the inability to completely eliminate leukemia stem cells, which results in relapse of disease posttreatment. To ensure that LSCs capable of inducing AML did not survive SKI-178 treatment, BM from both the 10 and 20 mg/kg SKI-178-treated mice was transplanted into secondary recipient mice. These mice were monitored for the development of disease for 6 weeks in the absence of treatment. None of these recipient mice developed disease and WBC counts at 6 weeks posttransplant for mice that received BM from either the 10 or 20 mg/kg SKI-178-treated donors were within the normal limit indicating that, indeed, SKI-178 induced complete remission of MLL-AF9 leukemia [ Figure 6d ]. The murine MLL-AF9 model of AML recapitulates many aspects of human AML, but human AML is a heterogeneous disease and cells often exhibit complex cytogenetics. Leukemia cells with multiple mutations often develop aggressive phenotypes. While the data presented above demonstrate the effectiveness of SKI-178 in vivo, the ability of SKI-178 to reduce the AML burden in mice-bearing human AML cells has not been established. To this end, we utilized a second AML model system by engrafting the human AML cell line, MOLM-13, into immunocompromised NOD.Cg-NSG mouse strain. MOLM-13 is an adult MLL-AF9 cell line carrying an FLT3-ITD mutated allele that induces very aggressive disease in immunocompromised mice. 63, 64 The FLT3-ITD mutation induces constitutive activation of JAK/STAT and Erk1/2 signaling leading to rapid proliferation contributing to the aggressiveness of MOLM-13 cell growth in vivo. Activation of STAT5-dependent signaling is known to promote leukemia stem cell self-renewal. Interestingly, we have recently shown that SKI-178 inhibits JAK/STAT signaling in natural killer-large granular lymphocyte leukemia (NK-LGL-leukemia). 65 Thus, it was of interest to determine whether SKI-178 affects JAK/STAT signaling in the MOLM-13 cell line. Indeed, as shown in Figure 7a , STAT5 is constitutively active (as judged by phosphorylation of Tyr694) in MOLM-13 cells. SKI-178 treatment of these cells abrogated phosphorylation/activation of Tyr694 of STAT5 as well as phosphorylation/activation of Erk1/2 (Thr202/Tyr204), suggesting that SKI-178 may have in vivo efficacy in an MOLM-13 xenograft model. We utilized MOLM-13 cells stably expressing luciferase (MOLM-13/Luc2) for noninvasive monitoring of disease burden. These cells were injected into NSG mice and the development of AML was monitored by in vivo imaging. As expected, SKI-178 treatment significantly reduced leukemia burden as determined by luciferase activity [ Figure 7b and c] and extended survival [ Figure 7d ] as compared to vehicle-treated controls.
SKI-178 effects on
DISCUSSION
We originally developed SKI-178 as a novel, SphK1-selective inhibitor and demonstrated that it was cytotoxic to a broad range of cancer cell lines including multidrug-resistant types. 24 Herein, we have employed the state-of-the-art CETSA technique to reexamine the isoform selectivity of SKI-178 in intact cells. This reanalysis has revealed that SKI-178 directly engages both SphK1 and SphK2 in cells, at concentrations consistent with the cytotoxic IC 50 of SKI-178, in multiple cancer cell lines.
The cytotoxicity of SKI-178 is at odds with a recent report claiming that inhibition of either SphK1 or SphK2 alone is not sufficient to induce apoptotic cell death. 19 Thus, we considered the possibility that SKI-178 may have additional targets that contribute to its cytotoxic effects. A detailed examination of the apoptotic mechanism of action of SKI-178 revealed that SKI-178-induced apoptotic cell death resulted from sustained CDK1 activation during prolonged mitotic arrest. 25 While SphK1 and SphK2 have been associated with mitotic arrest, we noted a striking similarity between the MOA of SKI-178 and various MTA. Thus, we examined the possibility that SKI-178, besides being a SphK inhibitor, also affects microtubule dynamics. To this end, we have presented evidence that SKI-178 indeed functions as an MTA, preventing the polymerization of the microtubule network both in vitro and in intact cells. Interestingly, we separately demonstrate that simultaneous inhibition of the SphKs and disruption of the microtubule network results in synergistic induction of apoptosis suggesting that the two activities of SKI-178 interact in a synergistic manner. We further demonstrate that SKI-178 is well tolerated in normal healthy mice, with little to no overt toxicity. Most importantly, we have also demonstrated that SKI-178 has therapeutic efficacy in several mouse models of AML. Together, these results established SKI-178 as a multitargeted inhibitor with promising chemotherapeutic potential.
Another interesting observation was the SKI-178-induced attenuation of STAT5 signaling in the FLT3-ITD AML cell line MOLM-13. FLT3 has been shown to induce production of IL-6 through activation of NF-κB signaling in AML cells. 66 Recently, an autocrine feed-forward loop between IL-6, SphK1/S1P, and STAT3 has been proposed in colorectal cancer. 67 The effects of SKI-178 on STAT3/5 signaling suggest that SphK1 may play a similar role in amplification of FLT3-induced STAT signaling in FLT3-ITD AMLs. This intriguing observation suggests that the ability of SKI-178 to inhibit JAK/STAT signaling would allow for the potential inclusion of SKI-178 in targeted therapeutic regimens for FLT3-ITD AMLs. Furthermore, inhibition of SphK1 activity using SKI-178 could represent an alternative strategy to block FLT3 signaling, especially in patients who have developed resistance to FLT3 inhibitors.
Personalized medicine and rational drug design have offered the hope of so-called "magic bullet" therapies that are highly potent and highly selective/specific for single-molecular targets. In cancer therapy, this approach was based primarily on the concept that driver mutations of proto-oncogenic proteins were directly linked to the development of cancer and that pharmacological inhibition of the deregulated target would, at a minimum, restore normal function or, preferentially, induce apoptosis. Unfortunately, despite a few modest success stories (i.e., imatinib), acquired drug resistance, the presence of multiple molecular alterations and the intrinsic clonal heterogeneity of primary tumors have all conspired to dampen the enthusiasm for "magic bullet" therapies for cancer.
As kinome profiling and direct target engagement assays have matured, it has become clear that the vast majority of "targeted therapies" modulate the activities of multiple cellular targets. However, it was soon realized that these multitargeted or "poly-pharmacological" agents had distinct advantages that made them attractive therapeutic strategies for anticancer therapy.
While there are numerous multitargeted agents in the literature, we believe that SKI-178 is unique and we have directly demonstrated that the two separate functional activities of SKI-178 (i.e., SphK Inhibition and Microtubule Disruption) synergize to induce apoptotic cell death in cancer cells. With regard to the further development of SKI-178, there are several paths forward in its development. First and foremost, SKI-178 represents a novel chemotype of MTA and could be further developed as such. However, the fact that SphK inhibition synergizes with disruption of the microtubule network indicates that there is a strong rationale for maintenance the multitargeted nature of SKI-178. Combined with our data demonstrating the therapeutic efficacy of SKI-178 in multiple mouse models of cancer, we believe that SKI-178 represents a unique class of multitargeted therapeutic agents that can and should be further optimized for therapeutic efficacy, potency, deliverability, and stability rather than for increased target selectivity or specificity.
A separate issue concerns the future of selective SphK inhibitor development. Based on the recent studies suggesting that targeting SphK1 and/or SphK2 alone is insufficient to affect cell viability, further efforts to discover and develop selective SphK1 and/or SphK2 inhibitors may not yield therapeutically active anticancer agents outright. 19 However, it is possible to envision other avenues for continued SKI development. One such avenue would be as adjuvants to currently approved chemotherapies, especially in patients with high SphK expression in their tumors (i.e., development of the SphKs as biomarkers). Indeed, there are numerous examples in the literature of SKIs interacting synergistically with both targeted and cytotoxic chemotherapies. 39, [68] [69] [70] A highly selective noncytotoxic SphK inhibitor, such as PF-543, may be an ideal adjuvant to current chemotherapeutic regimens. In such an instance, inhibition of S1P production and/or accumulation of Cer could enhance induction of apoptosis of the standard-of-care regimens. Another avenue of use for the currently available SKIs (such as PF-543) would be as chemical probes for the study of SphK1 and SphK2 biological functions. 71 Finally, identification of noncancerous diseases, where SphK inhibition, in the absence of induction of cellular cytotoxicity, would be preferable (such as sickle-cell anemia) could support further development of more selective SphK inhibitors.
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